Trastuzumab: Targeted therapy for the management of HER-2/neu- overexpressing metastatic breast cancer

American Journal of Therapeutics

Volumn 12, Issue 3, 2005, Pages 243-253

  Emens, Leisha A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Breast cancer; Chemotherapy; HER 2 neu; Targeted therapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; FULVESTRANT; GEFITINIB; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PARACETAMOL; PERTUZUMAB; PETHIDINE; PROGESTERONE RECEPTOR; TAMOXIFEN; THIOTEPA; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; DRUG ADDITIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HORMONE SENSITIVITY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TOXICITY; METASTASIS; MONOTHERAPY; NAUSEA; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 20444502625     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Osborne C. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46:2884-2888.
2. Osborne C. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000;18:3172-3186.
3. Dauvois S. Antiestrogen ICI 164,384 reduces cellular estrogen content by increasing its turnover. Proc Natl Acad Sci USA. 1992;89:4037-4041.
4. Goss PE. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001;19:881-894.
5. Slamon DJ. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
6. Slamon DJ. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
7. Ross J. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413-428.
8. Sorlie T. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
9. Sorlie T. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
10. Yarden Y. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
11. Moody S. Conditional activation of neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002;2:451-461.
12. Barnes D. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer. 1992;28:644-648.
13. Carter P. Humanization of an anti-pi85HER-2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285-4289.
14. Arteaga C. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing breast cancer. Breast Cancer Res. 2003;5:96-100.
15. Lee S. Enhanced sensitization to Taxol-induced apoptosis by Herceptin pretreatment in erbB2-overexpressing breast cancer cells. Cancer Res. 2002;62:5703-5710.
16. Chang J. Induction of apoptosis without change in cell proliferation in primary breast cancers with neoadjuvant trastuzumab. Breast Cancer Res Treat. 2003;82:abstract 24.
17. Pietras R. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999;59:1347-1355.
18. Mayfield S. DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines. Breast Cancer Res Treat. 2001;70:123-129.
19. Izumi Y. Herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279-280.
20. Clynes R. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
21. Kono K. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res. 2004;10:2538-2544.
22. zum Buschenfelde CM. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 2002;62:2244-2247.
23. + T cell effector function and tumor-free survival in HER-2/neu transgenic mice. J Immunol. 2003;15:2161-2169.
24. Baselga J. Recombinant humanized anti-HER2 antibody enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825-2831.
25. Pegram M. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18:2241-2251.
26. Pietras R. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 1998;17:2235-2249.
27. Pegram M. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96:739-749.
28. Argiris A. Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res. 2004;10:1409-1420.
29. Pietras R. Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat. 2003;82:S12.
30. Schiff R. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003;9:447S-454S.
31. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist. 2004;9:20-26.
32. Shou J. Mechanisms of tamoxifen resistance: increased estrogen-receptor-HER-2/neu cross-talk in ER/HER-2-positive breast cancer. J Natl Cancer Inst. 2004;96:926-935.
33. Moasser M. The tyrosine kinase inhibitor ZD 1839 (Iressa) inhibits HER-2-driven signaling and suppresses the growth of HER-2-overexpressing tumor cells. Cancer Res. 2001;61:7184-7188.
34. Moulder S. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD 1839 (Iressa) inhibits HER-2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001;61:8887-8895.
35. Normanno N. Cooperative inhibitory effect of ZD 1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol. 2002;13:65-72.
36. Warburton C. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD 1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res. 2004;10:2512-2524.
37. Nahta R. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64:2343-2346.
38. Harries M. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer. 2002;9:75-85.
39. Baselga J. Phase II study of weekly intravenous recombinant humanized anti-p185 (HER2) monoclonal antibody in patients with HER2-new-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737-744.
40. Pegram M. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p195HER2/neu monoclonal antibody plus cisplatin in patients with HER2/wew-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659-2671.
41. Cobleigh M. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
42. Slamon DJ. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
43. Vogel C. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
44. Osoba D. Effects of quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002;20:3106-3113.
45. Seidman AD. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215-1221.
46. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592-1600.
47. Perez E. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004;22:322-329.
48. Sawyer DB. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2. Circulation. 2002;105:1551-1554.
49. Dowsett M. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418-423.
50. Kostler W. Monitoring of serum HER-2/wew predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10:1618-1624.
51. Lipton A. Predicting response to Herceptin therapy. Clin Cancer Res. 2004;10:1559-1560.
52. Mass R. Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization. Breast Cancer Res Treat. 2001;213:abstract 18.
53. Seidman AD. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587-2595.
54. Esteva R Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800-1808.
55. Robert N. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat. 2002;76:S37.
56. Burstein H. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19:2722-2730.
57. Burstein H. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factor, and cardiac surveillance algorithm. J Clin Oncol. 2003;21:2889-2895.
58. Jahanzeb M. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist. 2002;7:410-417.
59. O'Shaughnessy J. Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol. 2003;30:22-26.
60. Sledge GW. Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. Semin Oncol. 2003;30:19-21.
61. Thomssen C. Cardiac safety of epirubicin/cyclophosphamide (EC) alone and in combination with Herceptin in women with metastatic breast cancer (MBC). Breast Cancer Res Treat. 2002;76:S111.
62. Theodoulou M. Preliminary cardiac safety and efficacy data from a phase I/II trial of TLC D-99 (D-99) and trastuzumab (T) in patients with locally advanced or metastatic breast cancer. Proceedings of the American Society of Clinical Oncology, 2002;abstract 20.
63. Pegram M. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER-2-positive advanced breast cancer. J Natl Cancer Inst. 2004;96:759-769.
64. Harris K. A population pharmacokinetic model for trastuzumab (Herceptin) and implications for clinical dosing. Proceedings of the American Society of Clinical Oncology, 2002;21 abstract 488.
65. Leyland-Jones B. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003;21:3965-3971.
66. Fisher B. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
67. Burstein J. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2-overexpressing stage II or III breast cancer a pilot study. J Clin Oncol. 2003;21:46-53.
68. Hurley J. Primary therapy with Herceptin, Taxotere and cisplatin in locally advanced and inflammatory breast cancer. Proceedings of the American Society of Clinical Oncology, 2001;20:abstract 1871.
69. Tan A. Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol. 2003;30:54-64.
70. Fleming G. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of Cancer and Leukemia Group B 9661. Clin Cancer Res. 2002;8:3718-3727.
71. Repka T. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res. 2003;9:2440-2446.
72. Parihar R. A phase I study of interleukin-12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon-γ production in a subset of patients. Clin Cancer Res. 2004;10:5027-5037.